Contineum Therapeutics EBIT

Contineum Therapeutics (CTNM) currently reports a EBIT of $-66M as of June 2026. That compares with $-62M in the prior-year period — down 7.7% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Contineum Therapeutics's EBIT history and peer comparisons.

Contineum Therapeutics's EBIT decreased from $-62M to $-66M — a 7.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Contineum Therapeutics's EBIT of $-66M is lower than the its sector sector average of $-6.4M. That is roughly 938.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Contineum Therapeutics reported $-66M in EBIT as of June 2026. That compares with $-62M in the prior-year period — down 7.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-66M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Contineum Therapeutics, and consider following CTNM for alerts when major investors trade the stock.